{"gene":"PIM1","run_date":"2026-06-10T06:43:35","timeline":{"discoveries":[{"year":1991,"finding":"Recombinant human PIM-1 protein exhibits exclusively serine/threonine kinase activity in vitro; it phosphorylates histone H1 (Km ~51 µM) and shows autophosphorylation activity. No tyrosine kinase activity was detected under any tested conditions.","method":"In vitro kinase assay with purified GST-PIM-1 fusion protein expressed in E. coli; substrates included histone H1 and various peptides; amino-terminal sequence analysis confirmed protein identity","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution with purified recombinant protein, multiple substrates tested, mutagenesis-validated kinase-dead control in follow-up work","pmids":["1713213"],"is_preprint":false},{"year":1992,"finding":"The substrate recognition sequence for PIM-1 kinase requires basic amino acid residues (Arg/Lys) on the amino-terminal side of the target Ser/Thr; optimal consensus is (Arg/Lys)3-X-Ser/Thr*-X'. A kinase-dead mutant (Lys67→Met) confirmed no contaminating kinase activity.","method":"In vitro kinase assays with synthetic peptide substrates and site-directed mutagenesis (Lys67Met active-site mutant); phosphopeptide analysis of histone H1","journal":"Archives of biochemistry and biophysics","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with mutagenesis, systematic peptide substrate profiling, replicated in later structural studies","pmids":["1416988"],"is_preprint":false},{"year":1998,"finding":"PIM-1 protein binds to p100 (a c-Myb transcriptional coactivator) via yeast two-hybrid and co-immunoprecipitation in animal cells, directly phosphorylates p100 in vitro, and functions downstream of Ras to stimulate c-Myb transcriptional activity in a p100-dependent manner.","method":"Yeast two-hybrid screen; in vitro kinase assay; co-immunoprecipitation in animal cells; transcriptional reporter assay","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP, in vitro phosphorylation, and functional reporter assay in single study with multiple orthogonal methods","pmids":["9809063"],"is_preprint":false},{"year":1999,"finding":"PIM-1 and c-Myc synergize downstream of STAT3/gp130 signaling to drive G1-to-S cell cycle progression and anti-apoptosis; a kinase-defective PIM-1 mutant attenuates gp130-mediated cell proliferation; VCP (valosine-containing protein) was identified as a downstream target gene of PIM-1 signaling.","method":"Kinase-dead PIM-1 mutant overexpression; constitutive expression rescue experiments; expression of mutant VCP leading to apoptosis; cytokine receptor signaling assays","journal":"Immunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — dominant-negative mutant with defined proliferation/apoptosis phenotype, multiple complementary genetic approaches, single lab","pmids":["10626893"],"is_preprint":false},{"year":2001,"finding":"PIM-1 physically interacts with Hsp90α and Hsp90β; the Hsp90 inhibitor geldanamycin induces rapid degradation of PIM-1 and reduces its kinase activity, indicating Hsp90 stabilizes and maintains PIM-1 function.","method":"Co-immunoprecipitation; treatment with Hsp90 inhibitor geldanamycin; kinase activity assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP plus pharmacological inhibition showing functional consequence, single lab","pmids":["11237709"],"is_preprint":false},{"year":2002,"finding":"PIM-1 associates with p21Cip1/WAF1, phosphorylates p21 in vitro (at residues 140-147 region) and in vivo, and co-transfection of wild-type PIM-1 with p21 results in cytoplasmic localization of p21, while kinase-dead PIM-1 results in nuclear localization; Thr145 is the phosphorylation site responsible for cytoplasmic localization.","method":"Pull-down assay; co-immunoprecipitation; in vitro kinase assay with recombinant proteins; phosphoamino acid assay; co-transfection with wild-type and kinase-dead PIM-1; subcellular fractionation","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation, site-specific mutagenesis, co-IP, and functional subcellular localization consequence, multiple orthogonal methods in single study","pmids":["12431783"],"is_preprint":false},{"year":2002,"finding":"PIM-1 dynamically redistributes during the cell cycle: it localizes to nucleus and cytoplasm during interphase but moves to spindle poles during mitosis. PIM-1 phosphorylates NuMA in vitro and co-immunoprecipitates with NuMA, HP1β, dynein, and dynactin in mitotically arrested HeLa cells; kinase-dead PIM-1 does not co-localize with NuMA at spindle poles and promotes apoptosis.","method":"Confocal microscopy (live-cell GFP fusion); co-immunoprecipitation; in vitro kinase assay with immunoprecipitated NuMA; nocodazole-arrested mitotic cells","journal":"Chromosoma","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, in vitro phosphorylation, live imaging with GFP-fusion and kinase-dead comparison, single lab","pmids":["12111331"],"is_preprint":false},{"year":2004,"finding":"PIM-1 inhibits STAT5-dependent transcription by interacting with SOCS1 and SOCS3 and potentiating their inhibitory effects, most likely via phosphorylation-mediated stabilization of SOCS proteins; PIM-1 does not directly phosphorylate or bind STAT5.","method":"Ectopic expression in FDCP1 myeloid cells; STAT5 tyrosine phosphorylation and DNA-binding assays; co-immunoprecipitation of PIM-1 with SOCS1/SOCS3","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding demonstrated by co-IP, functional transcriptional assay, explicit negative result for direct STAT5 binding, single lab","pmids":["14764533"],"is_preprint":false},{"year":2005,"finding":"Crystal structures of PIM-1 bound to a high-affinity peptide substrate with either AMP-PNP or a bisindolylmaleimide inhibitor revealed an unanticipated mode of recognition for basic residues upstream of the phosphorylation site. Peptide library screens defined PIM-1 substrate specificity, and the major site of PIM-1 autophosphorylation maps to a novel site diverging from its consensus phosphorylation motif.","method":"Crystal structure determination; oriented peptide library screen; in vitro kinase assays; active-site mutagenesis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with bound substrate/inhibitor, peptide library screen for substrate specificity, and autophosphorylation site mapping in single rigorous study","pmids":["16227208"],"is_preprint":false},{"year":2005,"finding":"PIM-1 directly interacts with and phosphorylates the N-terminal region of Cdc25C, enhances Cdc25C phosphatase activity, and promotes progression through the G2/M checkpoint; PIM-1 and Cdc25C co-localize in the cytoplasm of epithelial and myeloid cells.","method":"Biochemical phosphorylation assays; immunofluorescence co-localization; transfection with bleomycin-induced G2/M arrest; phosphatase activity assays","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphorylation, co-localization, and functional cell cycle assay, multiple methods in single lab","pmids":["16356754"],"is_preprint":false},{"year":2005,"finding":"PIM-1 protein stability is regulated by Hsp90 (stabilizing) and the ubiquitin-proteasome pathway (degrading): PIM-1 is ubiquitinated and degraded by the proteasome; Hsp70 associates with PIM-1 targeted for degradation; Hsp90 inhibitor geldanamycin prevents heat-shock-mediated PIM-1 stabilization. PIM-1 kinase activity is maintained when bound to either Hsp70 or Hsp90.","method":"Immunoprecipitation to detect ubiquitinated PIM-1; proteasome inhibitor PS-341; Hsp90 inhibitor geldanamycin; luminescence-based kinase assay; pulse-chase half-life measurements","journal":"Molecular cancer research : MCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct IP of ubiquitinated PIM-1, pharmacological inhibition studies with kinase activity readout, single lab with multiple orthogonal methods","pmids":["15798097"],"is_preprint":false},{"year":2006,"finding":"PIM-1 kinase phosphorylates RUNX1 and RUNX3 proteins and enhances RUNX1 transactivation activity in a dose-dependent manner; PIM-1 physically associates with RUNX1 and RUNX3 (co-precipitation and co-localization in cell culture), and this interaction was initially identified by yeast two-hybrid using the C-terminal part of RUNX3.","method":"Yeast two-hybrid; co-immunoprecipitation; co-localization by confocal microscopy; in vitro kinase assay; transcriptional reporter assay","journal":"BMC cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP and kinase assay, functional transcriptional data, single lab","pmids":["16684349"],"is_preprint":false},{"year":2007,"finding":"PIM-1 phosphorylates p21Cip1/WAF1 on Thr145 in vitro and in vivo; this phosphorylation promotes nuclear localization of p21 and its stabilization. Phosphorylation of Ser146 (indirect consequence of PIM-1 expression) promotes cytoplasmic localization. PIM-1 knockdown decreases proliferation of H1299 cells and soft agar growth.","method":"Site-directed mutagenesis of p21; phospho-specific antibodies; in vitro kinase assay with recombinant proteins; co-transfection; siRNA knockdown; immunofluorescence for subcellular localization","journal":"Molecular cancer research : MCR","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation at specific site confirmed by phospho-specific antibodies, site-directed mutagenesis, and direct subcellular localization consequence; multiple orthogonal methods in single lab","pmids":["17855660"],"is_preprint":false},{"year":2007,"finding":"PP2A negatively regulates PIM-1 protein levels through the B56β regulatory subunit: PIM-1 co-immunoprecipitates specifically with B56β (not other B subunits); knockdown of B56β increases PIM-1 half-life from 0.7 to 2.8 h and decreases PIM-1 ubiquitination. Pin1 (prolyl-isomerase) also binds PIM-1 and decreases its protein level, potentially allowing PP2A/B56β interaction.","method":"Co-immunoprecipitation; shRNA knockdown of B56β; pulse-chase experiments; ubiquitination assays; PP2A catalytic subunit overexpression; okadaic acid inhibitor","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific co-IP with B56β but not other subunits, shRNA rescue, ubiquitination assay, single lab with multiple methods","pmids":["17297438"],"is_preprint":false},{"year":2007,"finding":"HOXA9 protein directly binds the PIM1 promoter and induces PIM1 mRNA and protein expression in hematopoietic cells; PIM1 induction by HOXA9 increases phosphorylation and inactivation of proapoptotic BAD; Hoxa9-/- cells show increased apoptosis and decreased proliferation that are rescued by reintroduction of PIM1.","method":"Chromatin immunoprecipitation (ChIP) of HOXA9 at PIM1 promoter; Western blot; retroviral reintroduction; apoptosis and proliferation assays in Hoxa9-/- cells","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, genetic rescue experiment, functional BAD phosphorylation readout, single lab","pmids":["17327400"],"is_preprint":false},{"year":2007,"finding":"PIM-1 is a crucial downstream effector of AKT-mediated cardioprotection; Pim-1 deficiency abrogates AKT-associated cardioprotection after myocardial infarction or pressure overload. Transgenic PIM-1 overexpression inhibits cardiomyocyte apoptosis with concomitant increases in Bcl-2, Bcl-XL protein levels, and Bad phosphorylation. PIM-1 overexpression is associated with increased SERCA2a expression and enhanced calcium dynamics.","method":"Pim-1 knockout mice; cardiac-specific Pim-1 transgenic mice; myocardial infarction model; Western blot for Bcl-2, Bcl-XL, pBad; calcium transient measurements; echocardiography","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout and transgenic overexpression with multiple molecular and functional readouts, cardiac-specific transgenic model, replicated across multiple injury paradigms","pmids":["18037896"],"is_preprint":false},{"year":2008,"finding":"PIM-1 phosphorylates RUNX3 at four Ser/Thr residues within the Runt domain, stabilizes RUNX3 protein, and markedly alters RUNX3 cellular localization from the nucleus to the cytoplasm.","method":"In vitro phosphorylation assay; site-directed mutagenesis; co-immunoprecipitation; immunofluorescence subcellular localization; Western blot for protein stability","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro phosphorylation, specific site mutagenesis, localization consequence, single lab","pmids":["18767071"],"is_preprint":false},{"year":2009,"finding":"PIM1 directly phosphorylates PRAS40 at Thr246 (an AKT substrate site) independently of AKT activation; this phosphorylation reduces PRAS40 association with mTOR, thereby increasing mTOR-directed phosphorylation of 4EBP1 and p70S6K. PIM1 overexpression thus activates mTORC1 signaling.","method":"In vitro kinase assay with PRAS40; co-immunoprecipitation of PRAS40 with mTOR; Western blot for 4EBP1 and p70S6K phosphorylation; PIM1 kinase inhibitors; FDCP1 cell model","journal":"Cancer biology & therapy","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in vitro phosphorylation of PRAS40, co-IP demonstrating complex disruption, pharmacological inhibitor confirmation of pathway, multiple orthogonal methods","pmids":["19276681"],"is_preprint":false},{"year":2009,"finding":"PIM1 phosphorylates ASK1 specifically on Ser83 both in vitro and in vivo; PIM1 binds ASK1 by co-immunoprecipitation; this phosphorylation decreases ASK1 kinase activity, inhibits downstream JNK and p38 phosphorylation, suppresses caspase-3 activation, and reduces H2O2-induced apoptosis.","method":"In vitro kinase assay; co-immunoprecipitation; site-specific mutagenesis (Ser83); Western blot for JNK/p38/caspase-3 phosphorylation; PIM1 siRNA knockdown; H2O2-induced oxidative stress","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation at specific site, co-IP, site-directed mutagenesis, and downstream pathway readout with siRNA validation, multiple orthogonal methods","pmids":["19749799"],"is_preprint":false},{"year":2010,"finding":"PIM-1 directly interacts with and phosphorylates P-glycoprotein (Pgp/ABCB1); PIM-1 knockdown or inhibition decreases cellular and cell-surface 170-kDa Pgp with increased Pgp ubiquitination and proteasomal degradation; PIM-1 protects Pgp from proteolytic/proteasomal degradation and enables Pgp glycosylation and cell-surface translocation, thereby supporting drug efflux.","method":"GST pull-down; in vitro kinase assay; immunoblotting after cycloheximide treatment; flow cytometry; siRNA knockdown; glycosylation inhibitor (2-deoxy-D-glucose)","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct pulldown, in vitro phosphorylation, stability assay, glycosylation inhibitor, multiple orthogonal methods in single study","pmids":["20460432"],"is_preprint":false},{"year":2010,"finding":"PIM-1 kinase localizes to the mitochondrial fraction during ischemia/reperfusion; cardiac-specific overexpression of PIM-1 increases antiapoptotic Bcl-XL and Bcl-2, preserves inner mitochondrial membrane potential under oxidative stress, prevents calcium overload-induced mitochondrial swelling, and inhibits cytochrome c release from isolated mitochondria.","method":"Subcellular fractionation; Western blot; cardiac-specific transgenic overexpression; mitochondrial membrane potential assay; ultrastructural electron microscopy; cytochrome c release assay from isolated mitochondria","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — fractionation, transgenic model, multiple orthogonal mitochondrial integrity assays, mechanistically linked localization to function","pmids":["20203306"],"is_preprint":false},{"year":2010,"finding":"PIM kinase inhibition or Pim-1 siRNA activates AMPK by elevating AMP/ATP ratios, which in turn suppresses mTORC1 activity; triple-knockout MEFs lacking all Pim kinases show activated AMPK, reduced protein synthesis, and decreased cap-dependent translation. Pim-3 expression alone in TKO MEFs reverses AMPK activation.","method":"Pim triple-knockout MEFs; SMI-4a kinase inhibitor; siRNA; AMPK/mTORC1 phosphorylation assays; metabolic (AMP/ATP) measurements; cap-dependent translation assay; Pim-3 re-expression","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — triple-knockout genetic model plus pharmacological inhibitor plus siRNA, metabolic readout, rescued by re-expression; multiple approaches in one study","pmids":["21187426"],"is_preprint":false},{"year":2010,"finding":"PIM-1 is destabilized under ribosomal stress (ribosomal protein deficiency induced by RNAi or nucleolar inhibition); reduced PIM-1 levels lead to increased p27Kip1 and cell cycle arrest independently of p53; restoring PIM-1 level by transfection recovers cell growth. PIM-1 was also found to interact with ribosomal protein S19 and co-sediment with ribosomes.","method":"RNAi knockdown of ribosomal proteins; nucleolar inhibitor treatment; Western blot; co-sedimentation with ribosomes; PIM-1 transfection rescue; p27Kip1 assay in p53-deficient context","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNAi and pharmacological destabilization with rescue by PIM-1 reintroduction, co-sedimentation data, single lab","pmids":["20639905"],"is_preprint":false},{"year":2010,"finding":"Cardiac-specific PIM-1 overexpression stimulates asymmetric division of cardiac progenitor cells (CPCs): PIM-1 transgenic hearts show 65% asymmetric CPC division (vs. 26% in controls after infarction), as assessed by polarization of the cell fate determinant Numb in mitotic phospho-histone-positive CPCs.","method":"BrdU/Ki-67/c-Myc proliferation markers; confocal microscopy quantification of Numb and α-adaptin polarization; cardiac-specific Pim-1 transgenic mice; myocardial infarction model","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — transgenic overexpression with quantitative confocal microscopy for asymmetric division markers, single lab","pmids":["20075333"],"is_preprint":false},{"year":2014,"finding":"PIM-1 interacts with heterochromatin protein 1γ (HP1γ) and phosphorylates it on Ser93; this phosphorylation enhances HP1γ binding to H3K9me3, resulting in heterochromatin formation and suppression of proliferative genes (CCNA2, PCNA). IL-6/STAT3 signaling induces PIM-1 expression during senescence, linking cytokine signaling to heterochromatin formation via PIM-1.","method":"Co-immunoprecipitation; in vitro phosphorylation assay; site-specific mutagenesis (Ser93); ChIP for H3K9me3; ectopic PIM-1 expression inducing premature senescence; siRNA knockdown","journal":"Aging cell","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro phosphorylation at specific site, co-IP, ChIP demonstrating functional heterochromatin consequence, and genetic ectopic expression/knockdown, multiple orthogonal methods","pmids":["25040935"],"is_preprint":false},{"year":2021,"finding":"PIM1 regulates lipid oxidative metabolism in myeloid-derived suppressor cells (MDSCs) via PPARγ-mediated activities; enforced PPARγ expression rescues metabolic and functional defects in Pim1-/- MDSCs; pharmacologic PIM kinase inhibition disrupts myeloid immunosuppressive function and enhances CD8+ T-cell antitumor immunity.","method":"Pim1 knockout mice; single-cell RNA sequencing; PPARγ overexpression rescue in Pim1-/- MDSCs; AZD1208 pharmacological inhibitor; bilateral tumor model","journal":"Cancer immunology research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout, PPARγ rescue, pharmacological confirmation, functional immune assays, single lab","pmids":["33579728"],"is_preprint":false},{"year":2021,"finding":"GSK-3β phosphorylates PIM-1L at Ser95 and PIM-1S at Ser4, targeting PIM-1 for proteasomal degradation; this is downstream of AKT inactivation by PP2A-activating drugs and constitutively active AKT blocks this degradation.","method":"PP2A-activating drug treatment; constitutively active myristoylated AKT1 expression; GSK-3β inhibition; Western blot for Pim-1 proteasomal degradation; site-specific phosphorylation analysis","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological and genetic inhibition of pathway components, site-specific phosphorylation on PIM-1 identified, single lab","pmids":["33568357"],"is_preprint":false},{"year":2022,"finding":"PIM1 promotes IFN-β production by macrophages after TLR stimulation; PIM1 enhances IRF3 phosphorylation and nuclear translocation by promoting formation of signaling complexes composed of TRIF, TRAF3, TBK1, and IRF3 — this role is independent of PIM1 kinase activity. Pim1-/- mice produce less serum IFN-β after poly(I:C) challenge.","method":"Pim1-/- macrophages and mice; TLR3/TLR4 stimulation assays; IRF3 phosphorylation and nuclear translocation assays; co-immunoprecipitation of TRIF/TRAF3/TBK1/IRF3 complex; kinase-dead PIM1 experiments; poly(I:C) mouse challenge","journal":"Experimental & molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout model with co-IP of signaling complex, kinase-dead comparison distinguishing scaffolding from catalytic role, in vivo confirmation, single lab","pmids":["36446848"],"is_preprint":false},{"year":2010,"finding":"PIM-1 positively regulates RANKL-induced osteoclastogenesis; PIM-1 interacts with RANK and TAK1, and promotes RANKL-induced NF-κB activation via TAK1; overexpression of TAK1 rescues NF-κB activation in the presence of dominant-negative PIM-1. PIM-1 also regulates NFATc1 transcription and osteoclast-associated receptor expression.","method":"Dominant-negative PIM-1; RNA interference; overexpression of TAK1; co-immunoprecipitation of PIM-1 with RANK and TAK1; NF-κB and NFATc1 reporter assays; osteoclastogenesis assays","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of PIM-1 with RANK/TAK1, dominant-negative and RNAi experiments with TAK1 rescue, functional osteoclastogenesis readout, single lab","pmids":["21068407"],"is_preprint":false}],"current_model":"PIM1 is a constitutively active serine/threonine kinase (CAMK group) that phosphorylates a defined consensus motif [(Arg/Lys)3-X-Ser/Thr*] on substrates including p21Cip1 (Thr145), BAD, PRAS40 (Thr246), ASK1 (Ser83), Cdc25C, NuMA, RUNX1/3, HP1γ (Ser93), and P-glycoprotein, thereby promoting cell survival (via Bcl-2/Bcl-XL upregulation, Bad inactivation, ASK1 suppression), cell cycle progression (via p21 localization, Cdc25C activation, and AMPK/mTORC1 control), and mitochondrial integrity; its protein levels are regulated by Hsp90-mediated stabilization, ubiquitin-proteasome-mediated degradation directed by PP2A/B56β, and GSK-3β-mediated phosphorylation, while its transcription is induced downstream of JAK/STAT3, HOXA9, IL-6, and CEBPB; it also acts as a scaffold (independent of kinase activity) to promote IRF3-containing TLR signaling complexes for IFN-β production."},"narrative":{"mechanistic_narrative":"PIM1 is a constitutively active serine/threonine kinase that phosphorylates substrates bearing a basic consensus motif [(Arg/Lys)3-X-Ser/Thr] to promote cell survival, cell cycle progression, and resistance to apoptotic and metabolic stress [PMID:1713213, PMID:1416988, PMID:16227208]. Crystallographic and peptide-library analyses defined its substrate specificity and revealed an atypical mode of recognizing upstream basic residues, along with a non-canonical autophosphorylation site [PMID:16227208]. Catalytically, PIM1 phosphorylates a broad set of effectors to drive proliferation and survival: it modifies p21Cip1 at Thr145 to control its stability and nuclear/cytoplasmic partitioning [PMID:12431783, PMID:17855660]; activates Cdc25C to promote G2/M progression [PMID:16356754]; phosphorylates RUNX1/RUNX3 to alter their transactivation, stability, and localization [PMID:16684349, PMID:18767071]; phosphorylates HP1γ at Ser93 to enforce H3K9me3-dependent heterochromatin and senescence-associated gene silencing [PMID:25040935]; and phosphorylates PRAS40 at Thr246 to relieve mTORC1 inhibition, coupling PIM1 to AMPK/mTORC1 control of translation [PMID:19276681, PMID:21187426]. PIM1 enforces survival by phosphorylating ASK1 at Ser83 to suppress JNK/p38 and caspase-3 signaling [PMID:19749799] and, in cardiomyocytes, by upregulating Bcl-2/Bcl-XL, phosphorylating BAD, and preserving mitochondrial integrity downstream of AKT [PMID:18037896, PMID:20203306]. PIM1 abundance is dynamically controlled: Hsp90 (and Hsp70) stabilize the active kinase while the ubiquitin-proteasome system, PP2A through its B56β subunit, and GSK-3β-mediated phosphorylation drive its degradation [PMID:11237709, PMID:15798097, PMID:17297438, PMID:33568357]. Its transcription is induced by HOXA9 and by IL-6/STAT3 signaling, linking cytokine and oncogenic inputs to PIM1-dependent survival and senescence programs [PMID:17327400, PMID:25040935]. Beyond its catalytic functions, PIM1 acts as a kinase-independent scaffold promoting assembly of TRIF/TRAF3/TBK1/IRF3 complexes to drive IRF3 activation and IFN-β production after TLR stimulation [PMID:36446848].","teleology":[{"year":1991,"claim":"Establishing PIM1's enzymatic identity was the foundational question; the work showed it is exclusively a serine/threonine kinase with autophosphorylation activity and no tyrosine kinase activity.","evidence":"In vitro kinase assays with purified recombinant GST-PIM-1 on histone H1 and peptide substrates","pmids":["1713213"],"confidence":"High","gaps":["Did not define physiological substrates","No structural basis for catalysis"]},{"year":1992,"claim":"Defining how PIM1 selects substrates answered the specificity question, establishing a basic-residue consensus motif and confirming activity via a kinase-dead control.","evidence":"In vitro peptide substrate profiling and Lys67Met active-site mutagenesis","pmids":["1416988"],"confidence":"High","gaps":["Consensus derived from synthetic peptides, not endogenous substrates","No structural rationale until later"]},{"year":2005,"claim":"Crystal structures resolved the molecular basis for PIM1's recognition of upstream basic residues and mapped a non-canonical autophosphorylation site, grounding the consensus in atomic detail.","evidence":"Crystal structures with substrate peptide plus AMP-PNP or inhibitor, oriented peptide library screen, active-site mutagenesis","pmids":["16227208"],"confidence":"High","gaps":["Static structures do not capture regulation of activity in cells","Did not address protein-level regulation"]},{"year":2002,"claim":"Identifying p21Cip1 as a PIM1 substrate connected the kinase to cell cycle control, showing phosphorylation at Thr145 governs p21 subcellular localization.","evidence":"In vitro kinase assay, co-IP, kinase-dead comparison, and subcellular fractionation; later refined with phospho-specific antibodies and knockdown","pmids":["12431783","17855660"],"confidence":"High","gaps":["Apparent discrepancy in localization effect of Thr145 vs Ser146 phosphorylation","In vivo relevance across tissues not fully resolved"]},{"year":2005,"claim":"Linking PIM1 to Cdc25C and mitotic structures extended its cell cycle role to the G2/M transition and mitotic spindle apparatus.","evidence":"In vitro phosphorylation, co-localization, phosphatase assays, and GFP-fusion live imaging in mitotically arrested cells","pmids":["16356754","12111331"],"confidence":"Medium","gaps":["Spindle-pole substrate phosphorylation sites incomplete","Single-lab observations"]},{"year":2007,"claim":"Identifying ASK1 phosphorylation at Ser83 and BAD inactivation established the molecular basis of PIM1-mediated anti-apoptosis under stress.","evidence":"In vitro and in vivo phosphorylation, site mutagenesis, downstream JNK/p38/caspase readouts; HOXA9-driven BAD phosphorylation with genetic rescue","pmids":["19749799","17327400"],"confidence":"High","gaps":["Relative contribution of each survival substrate not quantified","Cell-type dependence unresolved"]},{"year":2009,"claim":"Phosphorylation of PRAS40 at Thr246 and subsequent AMPK/mTORC1 studies placed PIM1 within translational and metabolic control independently of AKT.","evidence":"In vitro kinase assay, co-IP showing mTOR complex disruption, inhibitor and Pim triple-knockout MEF metabolic and translation assays","pmids":["19276681","21187426"],"confidence":"High","gaps":["Direct vs indirect contributions to AMPK regulation not fully separated","In vivo metabolic consequences in normal tissue unclear"]},{"year":2008,"claim":"Demonstrating PIM1's cardioprotective role via AKT, Bcl-2/Bcl-XL, mitochondrial integrity, and progenitor division extended its function to tissue regeneration and stress survival.","evidence":"Pim-1 knockout and cardiac-specific transgenic mice, infarction models, mitochondrial integrity assays, asymmetric division quantification","pmids":["18037896","20203306","20075333"],"confidence":"High","gaps":["Mitochondrial substrates of PIM1 not defined","Mechanism of progenitor fate determination incomplete"]},{"year":2014,"claim":"Identifying HP1γ Ser93 phosphorylation revealed a chromatin-level function, coupling IL-6/STAT3-induced PIM1 to heterochromatin formation and senescence.","evidence":"Co-IP, in vitro site-specific phosphorylation, ChIP for H3K9me3, ectopic expression and knockdown inducing senescence","pmids":["25040935"],"confidence":"High","gaps":["Genome-wide scope of PIM1-dependent heterochromatin not mapped","Reconciliation of pro-proliferative and pro-senescent roles unresolved"]},{"year":2010,"claim":"Multiple regulatory studies established how PIM1 protein levels are controlled, defining Hsp90/Hsp70 stabilization, ubiquitin-proteasome degradation, and PP2A/B56β-directed turnover, later extended by GSK-3β phosphorylation.","evidence":"Co-IP, geldanamycin and proteasome inhibitors, B56β knockdown with half-life measurement, GSK-3β inhibition and constitutive AKT experiments","pmids":["11237709","15798097","17297438","33568357"],"confidence":"Medium","gaps":["E3 ligase directing PIM1 ubiquitination not identified","Hierarchy among regulatory inputs unclear"]},{"year":2022,"claim":"Distinguishing a kinase-independent scaffolding role showed PIM1 promotes IRF3-containing TLR signaling complexes for IFN-β production, broadening its function beyond catalysis.","evidence":"Pim1-/- macrophages and mice, kinase-dead comparison, co-IP of TRIF/TRAF3/TBK1/IRF3, poly(I:C) challenge; also implicated in RANKL/TAK1 osteoclast signaling","pmids":["36446848","21068407"],"confidence":"Medium","gaps":["Structural basis of scaffolding contacts undefined","Extent of kinase-independent roles across pathways unknown"]},{"year":null,"claim":"How PIM1 integrates its catalytic and scaffolding activities, and which substrates dominate in specific physiological versus oncogenic contexts, remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified substrate hierarchy across cell types","E3 ligase and full degradation circuitry incomplete","In vivo relevance of individual phosphorylation events not systematically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,1,5,9,11,16,17,18,24]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,1,8]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[27]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[7,9,17]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[5,6,16,24]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5,6,9]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[6]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[20]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[5,9,12]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[15,18,20]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[17,21,28]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[25,27,28]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[24]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[4,10,13,26]}],"complexes":[],"partners":["HSP90AA1","HSP90AB1","CDC25C","RUNX1","RUNX3","ASK1","PRAS40","HP1Γ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P11309","full_name":"Serine/threonine-protein kinase pim-1","aliases":[],"length_aa":313,"mass_kda":35.7,"function":"Proto-oncogene with serine/threonine kinase activity involved in cell survival and cell proliferation and thus providing a selective advantage in tumorigenesis (PubMed:15528381, PubMed:1825810, PubMed:31548394). Exerts its oncogenic activity through: the regulation of MYC transcriptional activity, the regulation of cell cycle progression and by phosphorylation and inhibition of proapoptotic proteins (BAD, MAP3K5, FOXO3) (PubMed:18593906). Phosphorylation of MYC leads to an increase of MYC protein stability and thereby an increase of transcriptional activity (By similarity). The stabilization of MYC exerted by PIM1 might explain partly the strong synergism between these two oncogenes in tumorigenesis (By similarity). Mediates survival signaling through phosphorylation of BAD, which induces release of the anti-apoptotic protein Bcl-X(L)/BCL2L1 (By similarity). Phosphorylation of MAP3K5, another proapoptotic protein, by PIM1, significantly decreases MAP3K5 kinase activity and inhibits MAP3K5-mediated phosphorylation of JNK and JNK/p38MAPK subsequently reducing caspase-3 activation and cell apoptosis (PubMed:19749799). Stimulates cell cycle progression at the G1-S and G2-M transitions by phosphorylation of CDC25A and CDC25C (PubMed:16356754). Phosphorylation of CDKN1A, a regulator of cell cycle progression at G1, results in the relocation of CDKN1A to the cytoplasm and enhanced CDKN1A protein stability (PubMed:12431783). Promotes cell cycle progression and tumorigenesis by down-regulating expression of a regulator of cell cycle progression, CDKN1B, at both transcriptional and post-translational levels (PubMed:18593906). Phosphorylation of CDKN1B, induces 14-3-3 proteins binding, nuclear export and proteasome-dependent degradation (PubMed:18593906). May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3 (PubMed:10664448). Also acts as a regulator of homing and migration of bone marrow cells involving functional interaction with the CXCL12-CXCR4 signaling axis (By similarity). Acts as a positive regulator of mTORC1 signaling by mediating phosphorylation and inhibition of DEPDC5 component of the GATOR1 complex (PubMed:31548394). Acts as a negative regulator of innate immunity by mediating phosphorylation and inactivation of GBP1 in absence of infection: phosphorylation of GBP1 induces interaction with 14-3-3 protein sigma (SFN) and retention in the cytosol (PubMed:37797010). Also phosphorylates and activates the ATP-binding cassette transporter ABCG2, allowing resistance to drugs through their excretion from cells (PubMed:18056989). Promotes brown adipocyte differentiation (By similarity)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P11309/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PIM1","classification":"Not Classified","n_dependent_lines":27,"n_total_lines":1208,"dependency_fraction":0.022350993377483443},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/PIM1","total_profiled":1310},"omim":[{"mim_id":"610580","title":"ONCOGENE PIM3; PIM3","url":"https://www.omim.org/entry/610580"},{"mim_id":"607505","title":"PAS DOMAIN-CONTAINING SERINE/THREONINE KINASE; PASK","url":"https://www.omim.org/entry/607505"},{"mim_id":"607331","title":"RP9 PRE-mRNA SPLICING FACTOR; RP9","url":"https://www.omim.org/entry/607331"},{"mim_id":"605257","title":"ACTIVATION-INDUCED CYTIDINE DEAMINASE; AICDA","url":"https://www.omim.org/entry/605257"},{"mim_id":"602503","title":"FREQUENTLY REARRANGED IN ADVANCED T-CELL LYMPHOMAS; FRAT1","url":"https://www.omim.org/entry/602503"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"bone marrow","ntpm":206.5}],"url":"https://www.proteinatlas.org/search/PIM1"},"hgnc":{"alias_symbol":[],"prev_symbol":["PIM"]},"alphafold":{"accession":"P11309","domains":[{"cath_id":"3.30.200.20","chopping":"37-120","consensus_level":"high","plddt":95.7754,"start":37,"end":120},{"cath_id":"1.10.510.10","chopping":"125-303","consensus_level":"high","plddt":98.1266,"start":125,"end":303}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11309","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11309-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11309-F1-predicted_aligned_error_v6.png","plddt_mean":89.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PIM1","jax_strain_url":"https://www.jax.org/strain/search?query=PIM1"},"sequence":{"accession":"P11309","fasta_url":"https://rest.uniprot.org/uniprotkb/P11309.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11309/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11309"}},"corpus_meta":[{"pmid":"10626893","id":"PMC_10626893","title":"Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.","date":"1999","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/10626893","citation_count":357,"is_preprint":false},{"pmid":"15694833","id":"PMC_15694833","title":"The serine/threonine kinase Pim-1.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15694833","citation_count":303,"is_preprint":false},{"pmid":"9809063","id":"PMC_9809063","title":"Pim-1 kinase and p100 cooperate to enhance c-Myb activity.","date":"1998","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/9809063","citation_count":218,"is_preprint":false},{"pmid":"18037896","id":"PMC_18037896","title":"Pim-1 regulates cardiomyocyte survival downstream of Akt.","date":"2007","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18037896","citation_count":193,"is_preprint":false},{"pmid":"12441685","id":"PMC_12441685","title":"Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis.","date":"2001","source":"Journal of veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/12441685","citation_count":183,"is_preprint":false},{"pmid":"12431783","id":"PMC_12431783","title":"Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase.","date":"2002","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12431783","citation_count":173,"is_preprint":false},{"pmid":"16227208","id":"PMC_16227208","title":"Structure and substrate specificity of the Pim-1 kinase.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16227208","citation_count":168,"is_preprint":false},{"pmid":"19072652","id":"PMC_19072652","title":"Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases.","date":"2009","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19072652","citation_count":148,"is_preprint":false},{"pmid":"7504280","id":"PMC_7504280","title":"Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7504280","citation_count":122,"is_preprint":false},{"pmid":"19276681","id":"PMC_19276681","title":"PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells.","date":"2009","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19276681","citation_count":117,"is_preprint":false},{"pmid":"8233823","id":"PMC_8233823","title":"In vivo analysis of Pim-1 deficiency.","date":"1993","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/8233823","citation_count":111,"is_preprint":false},{"pmid":"17855660","id":"PMC_17855660","title":"Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells.","date":"2007","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/17855660","citation_count":110,"is_preprint":false},{"pmid":"21187426","id":"PMC_21187426","title":"The Pim protein kinases regulate energy metabolism and cell growth.","date":"2010","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21187426","citation_count":108,"is_preprint":false},{"pmid":"21743487","id":"PMC_21743487","title":"The proto-oncogene Pim-1 is a target of miR-33a.","date":"2011","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/21743487","citation_count":108,"is_preprint":false},{"pmid":"16356754","id":"PMC_16356754","title":"The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16356754","citation_count":107,"is_preprint":false},{"pmid":"14764533","id":"PMC_14764533","title":"Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14764533","citation_count":106,"is_preprint":false},{"pmid":"15264249","id":"PMC_15264249","title":"Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer.","date":"2004","source":"The Prostate","url":"https://pubmed.ncbi.nlm.nih.gov/15264249","citation_count":106,"is_preprint":false},{"pmid":"30370255","id":"PMC_30370255","title":"PIM Kinase as an Executional Target in Cancer.","date":"2018","source":"Journal of cancer prevention","url":"https://pubmed.ncbi.nlm.nih.gov/30370255","citation_count":101,"is_preprint":false},{"pmid":"22385334","id":"PMC_22385334","title":"PIM1 kinase as a target for cancer therapy.","date":"2012","source":"Expert opinion on investigational drugs","url":"https://pubmed.ncbi.nlm.nih.gov/22385334","citation_count":99,"is_preprint":false},{"pmid":"12111331","id":"PMC_12111331","title":"Pim-1 associates with protein complexes necessary for mitosis.","date":"2002","source":"Chromosoma","url":"https://pubmed.ncbi.nlm.nih.gov/12111331","citation_count":96,"is_preprint":false},{"pmid":"26893828","id":"PMC_26893828","title":"Pim-1 kinase as cancer drug target: An update.","date":"2015","source":"Biomedical reports","url":"https://pubmed.ncbi.nlm.nih.gov/26893828","citation_count":95,"is_preprint":false},{"pmid":"19749799","id":"PMC_19749799","title":"PIM1 phosphorylates and negatively regulates ASK1-mediated apoptosis.","date":"2009","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19749799","citation_count":95,"is_preprint":false},{"pmid":"20919829","id":"PMC_20919829","title":"Why target PIM1 for cancer diagnosis and treatment?","date":"2010","source":"Future oncology (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20919829","citation_count":92,"is_preprint":false},{"pmid":"1713213","id":"PMC_1713213","title":"Recombinant human pim-1 protein exhibits serine/threonine kinase activity.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1713213","citation_count":89,"is_preprint":false},{"pmid":"15798097","id":"PMC_15798097","title":"Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway.","date":"2005","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/15798097","citation_count":89,"is_preprint":false},{"pmid":"20203306","id":"PMC_20203306","title":"Pim-1 kinase protects mitochondrial integrity in cardiomyocytes.","date":"2010","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/20203306","citation_count":88,"is_preprint":false},{"pmid":"25491234","id":"PMC_25491234","title":"Pim kinases in hematological malignancies: where are we now and where are we going?","date":"2014","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25491234","citation_count":79,"is_preprint":false},{"pmid":"23814490","id":"PMC_23814490","title":"Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma.","date":"2013","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23814490","citation_count":79,"is_preprint":false},{"pmid":"20460432","id":"PMC_20460432","title":"Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression.","date":"2010","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20460432","citation_count":79,"is_preprint":false},{"pmid":"26186558","id":"PMC_26186558","title":"Targeting the Pim kinases in multiple myeloma.","date":"2015","source":"Blood cancer journal","url":"https://pubmed.ncbi.nlm.nih.gov/26186558","citation_count":78,"is_preprint":false},{"pmid":"25104088","id":"PMC_25104088","title":"MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25104088","citation_count":77,"is_preprint":false},{"pmid":"21518143","id":"PMC_21518143","title":"Roles of Pim-3, a novel survival kinase, in tumorigenesis.","date":"2011","source":"Cancer science","url":"https://pubmed.ncbi.nlm.nih.gov/21518143","citation_count":75,"is_preprint":false},{"pmid":"20075333","id":"PMC_20075333","title":"Cardiac progenitor cell cycling stimulated by pim-1 kinase.","date":"2010","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/20075333","citation_count":73,"is_preprint":false},{"pmid":"11237709","id":"PMC_11237709","title":"Regulation of Pim-1 by Hsp90.","date":"2001","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/11237709","citation_count":72,"is_preprint":false},{"pmid":"30045021","id":"PMC_30045021","title":"The Natural Compound Myricetin Effectively Represses the Malignant Progression of Prostate Cancer by Inhibiting PIM1 and Disrupting the PIM1/CXCR4 Interaction.","date":"2018","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30045021","citation_count":72,"is_preprint":false},{"pmid":"17297438","id":"PMC_17297438","title":"Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.","date":"2007","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/17297438","citation_count":70,"is_preprint":false},{"pmid":"1416988","id":"PMC_1416988","title":"Characterization of the proto-oncogene pim-1: kinase activity and substrate recognition sequence.","date":"1992","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/1416988","citation_count":68,"is_preprint":false},{"pmid":"30954777","id":"PMC_30954777","title":"PIM kinase inhibitors: Structural and pharmacological perspectives.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30954777","citation_count":66,"is_preprint":false},{"pmid":"36694243","id":"PMC_36694243","title":"Targeting Pim kinases in hematological cancers: molecular and clinical review.","date":"2023","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/36694243","citation_count":66,"is_preprint":false},{"pmid":"20100002","id":"PMC_20100002","title":"Pim kinase inhibitors: a survey of the patent literature.","date":"2010","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/20100002","citation_count":66,"is_preprint":false},{"pmid":"22272708","id":"PMC_22272708","title":"The PIM kinases in hematological cancers.","date":"2012","source":"Expert review of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/22272708","citation_count":66,"is_preprint":false},{"pmid":"18042805","id":"PMC_18042805","title":"Pim-1 and Pim-2 kinases are required for efficient pre-B-cell transformation by v-Abl oncogene.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18042805","citation_count":66,"is_preprint":false},{"pmid":"21143989","id":"PMC_21143989","title":"Overexpression of Pim-1 in bladder cancer.","date":"2010","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/21143989","citation_count":64,"is_preprint":false},{"pmid":"15471855","id":"PMC_15471855","title":"Role of pim-1 in smooth muscle cell proliferation.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15471855","citation_count":63,"is_preprint":false},{"pmid":"17234686","id":"PMC_17234686","title":"Pim kinase substrate identification and specificity.","date":"2007","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17234686","citation_count":61,"is_preprint":false},{"pmid":"18784362","id":"PMC_18784362","title":"Pim-1 kinase antagonizes aspects of myocardial hypertrophy and compensation to pathological pressure overload.","date":"2008","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/18784362","citation_count":60,"is_preprint":false},{"pmid":"17327400","id":"PMC_17327400","title":"Evidence that the Pim1 kinase gene is a direct target of HOXA9.","date":"2007","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/17327400","citation_count":59,"is_preprint":false},{"pmid":"21601509","id":"PMC_21601509","title":"The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.","date":"2011","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/21601509","citation_count":57,"is_preprint":false},{"pmid":"25834102","id":"PMC_25834102","title":"PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25834102","citation_count":57,"is_preprint":false},{"pmid":"33579728","id":"PMC_33579728","title":"Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.","date":"2021","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/33579728","citation_count":56,"is_preprint":false},{"pmid":"10951575","id":"PMC_10951575","title":"Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death.","date":"2000","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/10951575","citation_count":56,"is_preprint":false},{"pmid":"29108877","id":"PMC_29108877","title":"PIM kinases: From survival factors to regulators of cell motility.","date":"2017","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29108877","citation_count":54,"is_preprint":false},{"pmid":"22273698","id":"PMC_22273698","title":"IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines.","date":"2012","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/22273698","citation_count":54,"is_preprint":false},{"pmid":"20639905","id":"PMC_20639905","title":"PIM1 kinase is destabilized by ribosomal stress causing inhibition of cell cycle progression.","date":"2010","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/20639905","citation_count":53,"is_preprint":false},{"pmid":"30791224","id":"PMC_30791224","title":"Pim-1 as a Therapeutic Target in Lupus Nephritis.","date":"2019","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/30791224","citation_count":51,"is_preprint":false},{"pmid":"16684349","id":"PMC_16684349","title":"Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity.","date":"2006","source":"BMC cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16684349","citation_count":51,"is_preprint":false},{"pmid":"21777193","id":"PMC_21777193","title":"The Pim kinases: new targets for drug development.","date":"2011","source":"Current drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/21777193","citation_count":50,"is_preprint":false},{"pmid":"25040935","id":"PMC_25040935","title":"PIM-1 modulates cellular senescence and links IL-6 signaling to heterochromatin formation.","date":"2014","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/25040935","citation_count":49,"is_preprint":false},{"pmid":"20667852","id":"PMC_20667852","title":"PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation.","date":"2010","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/20667852","citation_count":47,"is_preprint":false},{"pmid":"8660654","id":"PMC_8660654","title":"Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1.","date":"1996","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/8660654","citation_count":47,"is_preprint":false},{"pmid":"25121590","id":"PMC_25121590","title":"EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation.","date":"2014","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/25121590","citation_count":47,"is_preprint":false},{"pmid":"32473133","id":"PMC_32473133","title":"Resveratrol suppresses gastric cancer cell proliferation and survival through inhibition of PIM-1 kinase activity.","date":"2020","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/32473133","citation_count":44,"is_preprint":false},{"pmid":"28431341","id":"PMC_28431341","title":"Eco-friendly synthesis of novel cyanopyridine derivatives and their anticancer and PIM-1 kinase inhibitory activities.","date":"2017","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28431341","citation_count":42,"is_preprint":false},{"pmid":"25582332","id":"PMC_25582332","title":"Targeting Pim kinases for cancer treatment: opportunities and challenges.","date":"2015","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25582332","citation_count":40,"is_preprint":false},{"pmid":"19711112","id":"PMC_19711112","title":"Transcriptional regulation of Pim-1 kinase in vascular smooth muscle cells and its role for proliferation.","date":"2009","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19711112","citation_count":39,"is_preprint":false},{"pmid":"24155393","id":"PMC_24155393","title":"Kinase control of latent HIV-1 infection: PIM-1 kinase as a major contributor to HIV-1 reactivation.","date":"2013","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/24155393","citation_count":39,"is_preprint":false},{"pmid":"25155357","id":"PMC_25155357","title":"Pim1 kinase is upregulated in glioblastoma multiforme and mediates tumor cell survival.","date":"2014","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25155357","citation_count":38,"is_preprint":false},{"pmid":"16546353","id":"PMC_16546353","title":"Up-regulation of a serine-threonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma.","date":"2006","source":"International journal of oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16546353","citation_count":38,"is_preprint":false},{"pmid":"33414987","id":"PMC_33414987","title":"The role of Pim kinase in immunomodulation.","date":"2020","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/33414987","citation_count":37,"is_preprint":false},{"pmid":"21068407","id":"PMC_21068407","title":"Pim-1 regulates RANKL-induced osteoclastogenesis via NF-κB activation and NFATc1 induction.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21068407","citation_count":37,"is_preprint":false},{"pmid":"18767071","id":"PMC_18767071","title":"Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization.","date":"2008","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18767071","citation_count":37,"is_preprint":false},{"pmid":"34503111","id":"PMC_34503111","title":"PIM Kinases in Multiple Myeloma.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34503111","citation_count":30,"is_preprint":false},{"pmid":"21255581","id":"PMC_21255581","title":"Pim-1 kinase inhibits pathological injury by promoting cardioprotective signaling.","date":"2011","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/21255581","citation_count":27,"is_preprint":false},{"pmid":"30349298","id":"PMC_30349298","title":"Pim1 promotes cell proliferation and regulates glycolysis via interaction with MYC in ovarian cancer.","date":"2018","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30349298","citation_count":27,"is_preprint":false},{"pmid":"30204915","id":"PMC_30204915","title":"PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes.","date":"2019","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/30204915","citation_count":27,"is_preprint":false},{"pmid":"19934869","id":"PMC_19934869","title":"Differential role of Pim-1 kinase in anesthetic-induced and ischemic preconditioning against myocardial infarction.","date":"2009","source":"Anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/19934869","citation_count":27,"is_preprint":false},{"pmid":"16508102","id":"PMC_16508102","title":"Expression, purification, crystallization and preliminary crystallographic analysis of human Pim-1 kinase.","date":"2004","source":"Acta crystallographica. Section F, Structural biology and crystallization communications","url":"https://pubmed.ncbi.nlm.nih.gov/16508102","citation_count":27,"is_preprint":false},{"pmid":"34959179","id":"PMC_34959179","title":"Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.","date":"2021","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34959179","citation_count":27,"is_preprint":false},{"pmid":"31496730","id":"PMC_31496730","title":"PIM-1 kinase: a potential biomarker of triple-negative breast cancer.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31496730","citation_count":26,"is_preprint":false},{"pmid":"29854306","id":"PMC_29854306","title":"Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29854306","citation_count":26,"is_preprint":false},{"pmid":"21062737","id":"PMC_21062737","title":"Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21062737","citation_count":25,"is_preprint":false},{"pmid":"24737044","id":"PMC_24737044","title":"Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).","date":"2014","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/24737044","citation_count":24,"is_preprint":false},{"pmid":"16712793","id":"PMC_16712793","title":"Pim-1 kinase expression during murine mammary development.","date":"2006","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/16712793","citation_count":24,"is_preprint":false},{"pmid":"30033129","id":"PMC_30033129","title":"Targeting Pim Kinases and DAPK3 to Control Hypertension.","date":"2018","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30033129","citation_count":23,"is_preprint":false},{"pmid":"22451912","id":"PMC_22451912","title":"PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.","date":"2012","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/22451912","citation_count":23,"is_preprint":false},{"pmid":"22840454","id":"PMC_22840454","title":"Inhibition of Pim-1 attenuates the proliferation and migration in nasopharyngeal carcinoma cells.","date":"2012","source":"Asian Pacific journal of tropical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22840454","citation_count":23,"is_preprint":false},{"pmid":"31359998","id":"PMC_31359998","title":"A review on PIM kinases in tumors.","date":"2019","source":"Bioinformation","url":"https://pubmed.ncbi.nlm.nih.gov/31359998","citation_count":22,"is_preprint":false},{"pmid":"39487435","id":"PMC_39487435","title":"PIM1 kinase and its diverse substrate in solid tumors.","date":"2024","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39487435","citation_count":21,"is_preprint":false},{"pmid":"36446848","id":"PMC_36446848","title":"Pim1 promotes IFN-β production by interacting with IRF3.","date":"2022","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36446848","citation_count":21,"is_preprint":false},{"pmid":"33568357","id":"PMC_33568357","title":"PP2A-activating Drugs Enhance FLT3 Inhibitor Efficacy through AKT Inhibition-Dependent GSK-3β-Mediated c-Myc and Pim-1 Proteasomal Degradation.","date":"2021","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33568357","citation_count":20,"is_preprint":false},{"pmid":"38164076","id":"PMC_38164076","title":"Comprehensive Insights that Targeting PIM for Cancer Therapy: Prospects and Obstacles.","date":"2024","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38164076","citation_count":20,"is_preprint":false},{"pmid":"26687194","id":"PMC_26687194","title":"Clinical and biological significance of PIM1 kinase in osteosarcoma.","date":"2015","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/26687194","citation_count":20,"is_preprint":false},{"pmid":"25451079","id":"PMC_25451079","title":"Regulation of prostate stromal fibroblasts by the PIM1 protein kinase.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25451079","citation_count":20,"is_preprint":false},{"pmid":"36248187","id":"PMC_36248187","title":"Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling.","date":"2022","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/36248187","citation_count":20,"is_preprint":false},{"pmid":"19878356","id":"PMC_19878356","title":"PIM-1 kinase expression in adipocytic neoplasms: diagnostic and biological implications.","date":"2009","source":"International journal of experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19878356","citation_count":20,"is_preprint":false},{"pmid":"19895669","id":"PMC_19895669","title":"Pim-1 kinase as activator of the cell cycle pathway in neuronal death induced by DNA damage.","date":"2009","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19895669","citation_count":20,"is_preprint":false},{"pmid":"30464610","id":"PMC_30464610","title":"Downregulation of PIM1 regulates glycolysis and suppresses tumor progression in gallbladder cancer.","date":"2018","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/30464610","citation_count":20,"is_preprint":false},{"pmid":"25575657","id":"PMC_25575657","title":"Structure-based design of low-nanomolar PIM kinase inhibitors.","date":"2014","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/25575657","citation_count":19,"is_preprint":false},{"pmid":"33099167","id":"PMC_33099167","title":"New cyanopyridine-based scaffold as PIM-1 inhibitors and apoptotic inducers: Synthesis and SARs study.","date":"2020","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/33099167","citation_count":19,"is_preprint":false},{"pmid":"23004574","id":"PMC_23004574","title":"Insights from Pim1 structure for anti-cancer drug design.","date":"2012","source":"Expert opinion on drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/23004574","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48272,"output_tokens":8087,"usd":0.13306,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":35212,"output_tokens":8897,"usd":0.296752,"resynth_parse_fail":true,"stage2_stop_reason":"end_turn"},"total_usd":0.429812,"stage1_batch_id":"msgbatch_01CNoDbkChHEkgrJnL7BwtGJ","stage2_batch_id":"msgbatch_016Y4x9E9Wg5VQDANj9quSQD","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1991,\n      \"finding\": \"Recombinant human PIM-1 protein exhibits exclusively serine/threonine kinase activity in vitro; it phosphorylates histone H1 (Km ~51 µM) and shows autophosphorylation activity. No tyrosine kinase activity was detected under any tested conditions.\",\n      \"method\": \"In vitro kinase assay with purified GST-PIM-1 fusion protein expressed in E. coli; substrates included histone H1 and various peptides; amino-terminal sequence analysis confirmed protein identity\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution with purified recombinant protein, multiple substrates tested, mutagenesis-validated kinase-dead control in follow-up work\",\n      \"pmids\": [\"1713213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"The substrate recognition sequence for PIM-1 kinase requires basic amino acid residues (Arg/Lys) on the amino-terminal side of the target Ser/Thr; optimal consensus is (Arg/Lys)3-X-Ser/Thr*-X'. A kinase-dead mutant (Lys67→Met) confirmed no contaminating kinase activity.\",\n      \"method\": \"In vitro kinase assays with synthetic peptide substrates and site-directed mutagenesis (Lys67Met active-site mutant); phosphopeptide analysis of histone H1\",\n      \"journal\": \"Archives of biochemistry and biophysics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with mutagenesis, systematic peptide substrate profiling, replicated in later structural studies\",\n      \"pmids\": [\"1416988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"PIM-1 protein binds to p100 (a c-Myb transcriptional coactivator) via yeast two-hybrid and co-immunoprecipitation in animal cells, directly phosphorylates p100 in vitro, and functions downstream of Ras to stimulate c-Myb transcriptional activity in a p100-dependent manner.\",\n      \"method\": \"Yeast two-hybrid screen; in vitro kinase assay; co-immunoprecipitation in animal cells; transcriptional reporter assay\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP, in vitro phosphorylation, and functional reporter assay in single study with multiple orthogonal methods\",\n      \"pmids\": [\"9809063\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"PIM-1 and c-Myc synergize downstream of STAT3/gp130 signaling to drive G1-to-S cell cycle progression and anti-apoptosis; a kinase-defective PIM-1 mutant attenuates gp130-mediated cell proliferation; VCP (valosine-containing protein) was identified as a downstream target gene of PIM-1 signaling.\",\n      \"method\": \"Kinase-dead PIM-1 mutant overexpression; constitutive expression rescue experiments; expression of mutant VCP leading to apoptosis; cytokine receptor signaling assays\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — dominant-negative mutant with defined proliferation/apoptosis phenotype, multiple complementary genetic approaches, single lab\",\n      \"pmids\": [\"10626893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"PIM-1 physically interacts with Hsp90α and Hsp90β; the Hsp90 inhibitor geldanamycin induces rapid degradation of PIM-1 and reduces its kinase activity, indicating Hsp90 stabilizes and maintains PIM-1 function.\",\n      \"method\": \"Co-immunoprecipitation; treatment with Hsp90 inhibitor geldanamycin; kinase activity assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP plus pharmacological inhibition showing functional consequence, single lab\",\n      \"pmids\": [\"11237709\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PIM-1 associates with p21Cip1/WAF1, phosphorylates p21 in vitro (at residues 140-147 region) and in vivo, and co-transfection of wild-type PIM-1 with p21 results in cytoplasmic localization of p21, while kinase-dead PIM-1 results in nuclear localization; Thr145 is the phosphorylation site responsible for cytoplasmic localization.\",\n      \"method\": \"Pull-down assay; co-immunoprecipitation; in vitro kinase assay with recombinant proteins; phosphoamino acid assay; co-transfection with wild-type and kinase-dead PIM-1; subcellular fractionation\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation, site-specific mutagenesis, co-IP, and functional subcellular localization consequence, multiple orthogonal methods in single study\",\n      \"pmids\": [\"12431783\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PIM-1 dynamically redistributes during the cell cycle: it localizes to nucleus and cytoplasm during interphase but moves to spindle poles during mitosis. PIM-1 phosphorylates NuMA in vitro and co-immunoprecipitates with NuMA, HP1β, dynein, and dynactin in mitotically arrested HeLa cells; kinase-dead PIM-1 does not co-localize with NuMA at spindle poles and promotes apoptosis.\",\n      \"method\": \"Confocal microscopy (live-cell GFP fusion); co-immunoprecipitation; in vitro kinase assay with immunoprecipitated NuMA; nocodazole-arrested mitotic cells\",\n      \"journal\": \"Chromosoma\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, in vitro phosphorylation, live imaging with GFP-fusion and kinase-dead comparison, single lab\",\n      \"pmids\": [\"12111331\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"PIM-1 inhibits STAT5-dependent transcription by interacting with SOCS1 and SOCS3 and potentiating their inhibitory effects, most likely via phosphorylation-mediated stabilization of SOCS proteins; PIM-1 does not directly phosphorylate or bind STAT5.\",\n      \"method\": \"Ectopic expression in FDCP1 myeloid cells; STAT5 tyrosine phosphorylation and DNA-binding assays; co-immunoprecipitation of PIM-1 with SOCS1/SOCS3\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding demonstrated by co-IP, functional transcriptional assay, explicit negative result for direct STAT5 binding, single lab\",\n      \"pmids\": [\"14764533\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Crystal structures of PIM-1 bound to a high-affinity peptide substrate with either AMP-PNP or a bisindolylmaleimide inhibitor revealed an unanticipated mode of recognition for basic residues upstream of the phosphorylation site. Peptide library screens defined PIM-1 substrate specificity, and the major site of PIM-1 autophosphorylation maps to a novel site diverging from its consensus phosphorylation motif.\",\n      \"method\": \"Crystal structure determination; oriented peptide library screen; in vitro kinase assays; active-site mutagenesis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with bound substrate/inhibitor, peptide library screen for substrate specificity, and autophosphorylation site mapping in single rigorous study\",\n      \"pmids\": [\"16227208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PIM-1 directly interacts with and phosphorylates the N-terminal region of Cdc25C, enhances Cdc25C phosphatase activity, and promotes progression through the G2/M checkpoint; PIM-1 and Cdc25C co-localize in the cytoplasm of epithelial and myeloid cells.\",\n      \"method\": \"Biochemical phosphorylation assays; immunofluorescence co-localization; transfection with bleomycin-induced G2/M arrest; phosphatase activity assays\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphorylation, co-localization, and functional cell cycle assay, multiple methods in single lab\",\n      \"pmids\": [\"16356754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"PIM-1 protein stability is regulated by Hsp90 (stabilizing) and the ubiquitin-proteasome pathway (degrading): PIM-1 is ubiquitinated and degraded by the proteasome; Hsp70 associates with PIM-1 targeted for degradation; Hsp90 inhibitor geldanamycin prevents heat-shock-mediated PIM-1 stabilization. PIM-1 kinase activity is maintained when bound to either Hsp70 or Hsp90.\",\n      \"method\": \"Immunoprecipitation to detect ubiquitinated PIM-1; proteasome inhibitor PS-341; Hsp90 inhibitor geldanamycin; luminescence-based kinase assay; pulse-chase half-life measurements\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct IP of ubiquitinated PIM-1, pharmacological inhibition studies with kinase activity readout, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"15798097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"PIM-1 kinase phosphorylates RUNX1 and RUNX3 proteins and enhances RUNX1 transactivation activity in a dose-dependent manner; PIM-1 physically associates with RUNX1 and RUNX3 (co-precipitation and co-localization in cell culture), and this interaction was initially identified by yeast two-hybrid using the C-terminal part of RUNX3.\",\n      \"method\": \"Yeast two-hybrid; co-immunoprecipitation; co-localization by confocal microscopy; in vitro kinase assay; transcriptional reporter assay\",\n      \"journal\": \"BMC cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — yeast two-hybrid confirmed by co-IP and kinase assay, functional transcriptional data, single lab\",\n      \"pmids\": [\"16684349\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIM-1 phosphorylates p21Cip1/WAF1 on Thr145 in vitro and in vivo; this phosphorylation promotes nuclear localization of p21 and its stabilization. Phosphorylation of Ser146 (indirect consequence of PIM-1 expression) promotes cytoplasmic localization. PIM-1 knockdown decreases proliferation of H1299 cells and soft agar growth.\",\n      \"method\": \"Site-directed mutagenesis of p21; phospho-specific antibodies; in vitro kinase assay with recombinant proteins; co-transfection; siRNA knockdown; immunofluorescence for subcellular localization\",\n      \"journal\": \"Molecular cancer research : MCR\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation at specific site confirmed by phospho-specific antibodies, site-directed mutagenesis, and direct subcellular localization consequence; multiple orthogonal methods in single lab\",\n      \"pmids\": [\"17855660\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PP2A negatively regulates PIM-1 protein levels through the B56β regulatory subunit: PIM-1 co-immunoprecipitates specifically with B56β (not other B subunits); knockdown of B56β increases PIM-1 half-life from 0.7 to 2.8 h and decreases PIM-1 ubiquitination. Pin1 (prolyl-isomerase) also binds PIM-1 and decreases its protein level, potentially allowing PP2A/B56β interaction.\",\n      \"method\": \"Co-immunoprecipitation; shRNA knockdown of B56β; pulse-chase experiments; ubiquitination assays; PP2A catalytic subunit overexpression; okadaic acid inhibitor\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific co-IP with B56β but not other subunits, shRNA rescue, ubiquitination assay, single lab with multiple methods\",\n      \"pmids\": [\"17297438\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"HOXA9 protein directly binds the PIM1 promoter and induces PIM1 mRNA and protein expression in hematopoietic cells; PIM1 induction by HOXA9 increases phosphorylation and inactivation of proapoptotic BAD; Hoxa9-/- cells show increased apoptosis and decreased proliferation that are rescued by reintroduction of PIM1.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) of HOXA9 at PIM1 promoter; Western blot; retroviral reintroduction; apoptosis and proliferation assays in Hoxa9-/- cells\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct promoter binding, genetic rescue experiment, functional BAD phosphorylation readout, single lab\",\n      \"pmids\": [\"17327400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"PIM-1 is a crucial downstream effector of AKT-mediated cardioprotection; Pim-1 deficiency abrogates AKT-associated cardioprotection after myocardial infarction or pressure overload. Transgenic PIM-1 overexpression inhibits cardiomyocyte apoptosis with concomitant increases in Bcl-2, Bcl-XL protein levels, and Bad phosphorylation. PIM-1 overexpression is associated with increased SERCA2a expression and enhanced calcium dynamics.\",\n      \"method\": \"Pim-1 knockout mice; cardiac-specific Pim-1 transgenic mice; myocardial infarction model; Western blot for Bcl-2, Bcl-XL, pBad; calcium transient measurements; echocardiography\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout and transgenic overexpression with multiple molecular and functional readouts, cardiac-specific transgenic model, replicated across multiple injury paradigms\",\n      \"pmids\": [\"18037896\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"PIM-1 phosphorylates RUNX3 at four Ser/Thr residues within the Runt domain, stabilizes RUNX3 protein, and markedly alters RUNX3 cellular localization from the nucleus to the cytoplasm.\",\n      \"method\": \"In vitro phosphorylation assay; site-directed mutagenesis; co-immunoprecipitation; immunofluorescence subcellular localization; Western blot for protein stability\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro phosphorylation, specific site mutagenesis, localization consequence, single lab\",\n      \"pmids\": [\"18767071\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM1 directly phosphorylates PRAS40 at Thr246 (an AKT substrate site) independently of AKT activation; this phosphorylation reduces PRAS40 association with mTOR, thereby increasing mTOR-directed phosphorylation of 4EBP1 and p70S6K. PIM1 overexpression thus activates mTORC1 signaling.\",\n      \"method\": \"In vitro kinase assay with PRAS40; co-immunoprecipitation of PRAS40 with mTOR; Western blot for 4EBP1 and p70S6K phosphorylation; PIM1 kinase inhibitors; FDCP1 cell model\",\n      \"journal\": \"Cancer biology & therapy\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in vitro phosphorylation of PRAS40, co-IP demonstrating complex disruption, pharmacological inhibitor confirmation of pathway, multiple orthogonal methods\",\n      \"pmids\": [\"19276681\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"PIM1 phosphorylates ASK1 specifically on Ser83 both in vitro and in vivo; PIM1 binds ASK1 by co-immunoprecipitation; this phosphorylation decreases ASK1 kinase activity, inhibits downstream JNK and p38 phosphorylation, suppresses caspase-3 activation, and reduces H2O2-induced apoptosis.\",\n      \"method\": \"In vitro kinase assay; co-immunoprecipitation; site-specific mutagenesis (Ser83); Western blot for JNK/p38/caspase-3 phosphorylation; PIM1 siRNA knockdown; H2O2-induced oxidative stress\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation at specific site, co-IP, site-directed mutagenesis, and downstream pathway readout with siRNA validation, multiple orthogonal methods\",\n      \"pmids\": [\"19749799\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM-1 directly interacts with and phosphorylates P-glycoprotein (Pgp/ABCB1); PIM-1 knockdown or inhibition decreases cellular and cell-surface 170-kDa Pgp with increased Pgp ubiquitination and proteasomal degradation; PIM-1 protects Pgp from proteolytic/proteasomal degradation and enables Pgp glycosylation and cell-surface translocation, thereby supporting drug efflux.\",\n      \"method\": \"GST pull-down; in vitro kinase assay; immunoblotting after cycloheximide treatment; flow cytometry; siRNA knockdown; glycosylation inhibitor (2-deoxy-D-glucose)\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct pulldown, in vitro phosphorylation, stability assay, glycosylation inhibitor, multiple orthogonal methods in single study\",\n      \"pmids\": [\"20460432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM-1 kinase localizes to the mitochondrial fraction during ischemia/reperfusion; cardiac-specific overexpression of PIM-1 increases antiapoptotic Bcl-XL and Bcl-2, preserves inner mitochondrial membrane potential under oxidative stress, prevents calcium overload-induced mitochondrial swelling, and inhibits cytochrome c release from isolated mitochondria.\",\n      \"method\": \"Subcellular fractionation; Western blot; cardiac-specific transgenic overexpression; mitochondrial membrane potential assay; ultrastructural electron microscopy; cytochrome c release assay from isolated mitochondria\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — fractionation, transgenic model, multiple orthogonal mitochondrial integrity assays, mechanistically linked localization to function\",\n      \"pmids\": [\"20203306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM kinase inhibition or Pim-1 siRNA activates AMPK by elevating AMP/ATP ratios, which in turn suppresses mTORC1 activity; triple-knockout MEFs lacking all Pim kinases show activated AMPK, reduced protein synthesis, and decreased cap-dependent translation. Pim-3 expression alone in TKO MEFs reverses AMPK activation.\",\n      \"method\": \"Pim triple-knockout MEFs; SMI-4a kinase inhibitor; siRNA; AMPK/mTORC1 phosphorylation assays; metabolic (AMP/ATP) measurements; cap-dependent translation assay; Pim-3 re-expression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — triple-knockout genetic model plus pharmacological inhibitor plus siRNA, metabolic readout, rescued by re-expression; multiple approaches in one study\",\n      \"pmids\": [\"21187426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM-1 is destabilized under ribosomal stress (ribosomal protein deficiency induced by RNAi or nucleolar inhibition); reduced PIM-1 levels lead to increased p27Kip1 and cell cycle arrest independently of p53; restoring PIM-1 level by transfection recovers cell growth. PIM-1 was also found to interact with ribosomal protein S19 and co-sediment with ribosomes.\",\n      \"method\": \"RNAi knockdown of ribosomal proteins; nucleolar inhibitor treatment; Western blot; co-sedimentation with ribosomes; PIM-1 transfection rescue; p27Kip1 assay in p53-deficient context\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNAi and pharmacological destabilization with rescue by PIM-1 reintroduction, co-sedimentation data, single lab\",\n      \"pmids\": [\"20639905\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Cardiac-specific PIM-1 overexpression stimulates asymmetric division of cardiac progenitor cells (CPCs): PIM-1 transgenic hearts show 65% asymmetric CPC division (vs. 26% in controls after infarction), as assessed by polarization of the cell fate determinant Numb in mitotic phospho-histone-positive CPCs.\",\n      \"method\": \"BrdU/Ki-67/c-Myc proliferation markers; confocal microscopy quantification of Numb and α-adaptin polarization; cardiac-specific Pim-1 transgenic mice; myocardial infarction model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — transgenic overexpression with quantitative confocal microscopy for asymmetric division markers, single lab\",\n      \"pmids\": [\"20075333\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PIM-1 interacts with heterochromatin protein 1γ (HP1γ) and phosphorylates it on Ser93; this phosphorylation enhances HP1γ binding to H3K9me3, resulting in heterochromatin formation and suppression of proliferative genes (CCNA2, PCNA). IL-6/STAT3 signaling induces PIM-1 expression during senescence, linking cytokine signaling to heterochromatin formation via PIM-1.\",\n      \"method\": \"Co-immunoprecipitation; in vitro phosphorylation assay; site-specific mutagenesis (Ser93); ChIP for H3K9me3; ectopic PIM-1 expression inducing premature senescence; siRNA knockdown\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro phosphorylation at specific site, co-IP, ChIP demonstrating functional heterochromatin consequence, and genetic ectopic expression/knockdown, multiple orthogonal methods\",\n      \"pmids\": [\"25040935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"PIM1 regulates lipid oxidative metabolism in myeloid-derived suppressor cells (MDSCs) via PPARγ-mediated activities; enforced PPARγ expression rescues metabolic and functional defects in Pim1-/- MDSCs; pharmacologic PIM kinase inhibition disrupts myeloid immunosuppressive function and enhances CD8+ T-cell antitumor immunity.\",\n      \"method\": \"Pim1 knockout mice; single-cell RNA sequencing; PPARγ overexpression rescue in Pim1-/- MDSCs; AZD1208 pharmacological inhibitor; bilateral tumor model\",\n      \"journal\": \"Cancer immunology research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout, PPARγ rescue, pharmacological confirmation, functional immune assays, single lab\",\n      \"pmids\": [\"33579728\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GSK-3β phosphorylates PIM-1L at Ser95 and PIM-1S at Ser4, targeting PIM-1 for proteasomal degradation; this is downstream of AKT inactivation by PP2A-activating drugs and constitutively active AKT blocks this degradation.\",\n      \"method\": \"PP2A-activating drug treatment; constitutively active myristoylated AKT1 expression; GSK-3β inhibition; Western blot for Pim-1 proteasomal degradation; site-specific phosphorylation analysis\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological and genetic inhibition of pathway components, site-specific phosphorylation on PIM-1 identified, single lab\",\n      \"pmids\": [\"33568357\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PIM1 promotes IFN-β production by macrophages after TLR stimulation; PIM1 enhances IRF3 phosphorylation and nuclear translocation by promoting formation of signaling complexes composed of TRIF, TRAF3, TBK1, and IRF3 — this role is independent of PIM1 kinase activity. Pim1-/- mice produce less serum IFN-β after poly(I:C) challenge.\",\n      \"method\": \"Pim1-/- macrophages and mice; TLR3/TLR4 stimulation assays; IRF3 phosphorylation and nuclear translocation assays; co-immunoprecipitation of TRIF/TRAF3/TBK1/IRF3 complex; kinase-dead PIM1 experiments; poly(I:C) mouse challenge\",\n      \"journal\": \"Experimental & molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout model with co-IP of signaling complex, kinase-dead comparison distinguishing scaffolding from catalytic role, in vivo confirmation, single lab\",\n      \"pmids\": [\"36446848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"PIM-1 positively regulates RANKL-induced osteoclastogenesis; PIM-1 interacts with RANK and TAK1, and promotes RANKL-induced NF-κB activation via TAK1; overexpression of TAK1 rescues NF-κB activation in the presence of dominant-negative PIM-1. PIM-1 also regulates NFATc1 transcription and osteoclast-associated receptor expression.\",\n      \"method\": \"Dominant-negative PIM-1; RNA interference; overexpression of TAK1; co-immunoprecipitation of PIM-1 with RANK and TAK1; NF-κB and NFATc1 reporter assays; osteoclastogenesis assays\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of PIM-1 with RANK/TAK1, dominant-negative and RNAi experiments with TAK1 rescue, functional osteoclastogenesis readout, single lab\",\n      \"pmids\": [\"21068407\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PIM1 is a constitutively active serine/threonine kinase (CAMK group) that phosphorylates a defined consensus motif [(Arg/Lys)3-X-Ser/Thr*] on substrates including p21Cip1 (Thr145), BAD, PRAS40 (Thr246), ASK1 (Ser83), Cdc25C, NuMA, RUNX1/3, HP1γ (Ser93), and P-glycoprotein, thereby promoting cell survival (via Bcl-2/Bcl-XL upregulation, Bad inactivation, ASK1 suppression), cell cycle progression (via p21 localization, Cdc25C activation, and AMPK/mTORC1 control), and mitochondrial integrity; its protein levels are regulated by Hsp90-mediated stabilization, ubiquitin-proteasome-mediated degradation directed by PP2A/B56β, and GSK-3β-mediated phosphorylation, while its transcription is induced downstream of JAK/STAT3, HOXA9, IL-6, and CEBPB; it also acts as a scaffold (independent of kinase activity) to promote IRF3-containing TLR signaling complexes for IFN-β production.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"PIM1 is a constitutively active serine/threonine kinase that phosphorylates substrates bearing a basic consensus motif [(Arg/Lys)3-X-Ser/Thr] to promote cell survival, cell cycle progression, and resistance to apoptotic and metabolic stress [#0, #1, #8]. Crystallographic and peptide-library analyses defined its substrate specificity and revealed an atypical mode of recognizing upstream basic residues, along with a non-canonical autophosphorylation site [#8]. Catalytically, PIM1 phosphorylates a broad set of effectors to drive proliferation and survival: it modifies p21Cip1 at Thr145 to control its stability and nuclear/cytoplasmic partitioning [#5, #12]; activates Cdc25C to promote G2/M progression [#9]; phosphorylates RUNX1/RUNX3 to alter their transactivation, stability, and localization [#11, #16]; phosphorylates HP1\\u03b3 at Ser93 to enforce H3K9me3-dependent heterochromatin and senescence-associated gene silencing [#24]; and phosphorylates PRAS40 at Thr246 to relieve mTORC1 inhibition, coupling PIM1 to AMPK/mTORC1 control of translation [#17, #21]. PIM1 enforces survival by phosphorylating ASK1 at Ser83 to suppress JNK/p38 and caspase-3 signaling [#18] and, in cardiomyocytes, by upregulating Bcl-2/Bcl-XL, phosphorylating BAD, and preserving mitochondrial integrity downstream of AKT [#15, #20]. PIM1 abundance is dynamically controlled: Hsp90 (and Hsp70) stabilize the active kinase while the ubiquitin-proteasome system, PP2A through its B56\\u03b2 subunit, and GSK-3\\u03b2-mediated phosphorylation drive its degradation [#4, #10, #13, #26]. Its transcription is induced by HOXA9 and by IL-6/STAT3 signaling, linking cytokine and oncogenic inputs to PIM1-dependent survival and senescence programs [#14, #24]. Beyond its catalytic functions, PIM1 acts as a kinase-independent scaffold promoting assembly of TRIF/TRAF3/TBK1/IRF3 complexes to drive IRF3 activation and IFN-\\u03b2 production after TLR stimulation [#27].\",\n  \"teleology\": [\n    {\n      \"year\": 1991,\n      \"claim\": \"Establishing PIM1's enzymatic identity was the foundational question; the work showed it is exclusively a serine/threonine kinase with autophosphorylation activity and no tyrosine kinase activity.\",\n      \"evidence\": \"In vitro kinase assays with purified recombinant GST-PIM-1 on histone H1 and peptide substrates\",\n      \"pmids\": [\"1713213\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define physiological substrates\", \"No structural basis for catalysis\"]\n    },\n    {\n      \"year\": 1992,\n      \"claim\": \"Defining how PIM1 selects substrates answered the specificity question, establishing a basic-residue consensus motif and confirming activity via a kinase-dead control.\",\n      \"evidence\": \"In vitro peptide substrate profiling and Lys67Met active-site mutagenesis\",\n      \"pmids\": [\"1416988\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Consensus derived from synthetic peptides, not endogenous substrates\", \"No structural rationale until later\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Crystal structures resolved the molecular basis for PIM1's recognition of upstream basic residues and mapped a non-canonical autophosphorylation site, grounding the consensus in atomic detail.\",\n      \"evidence\": \"Crystal structures with substrate peptide plus AMP-PNP or inhibitor, oriented peptide library screen, active-site mutagenesis\",\n      \"pmids\": [\"16227208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Static structures do not capture regulation of activity in cells\", \"Did not address protein-level regulation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying p21Cip1 as a PIM1 substrate connected the kinase to cell cycle control, showing phosphorylation at Thr145 governs p21 subcellular localization.\",\n      \"evidence\": \"In vitro kinase assay, co-IP, kinase-dead comparison, and subcellular fractionation; later refined with phospho-specific antibodies and knockdown\",\n      \"pmids\": [\"12431783\", \"17855660\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Apparent discrepancy in localization effect of Thr145 vs Ser146 phosphorylation\", \"In vivo relevance across tissues not fully resolved\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Linking PIM1 to Cdc25C and mitotic structures extended its cell cycle role to the G2/M transition and mitotic spindle apparatus.\",\n      \"evidence\": \"In vitro phosphorylation, co-localization, phosphatase assays, and GFP-fusion live imaging in mitotically arrested cells\",\n      \"pmids\": [\"16356754\", \"12111331\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Spindle-pole substrate phosphorylation sites incomplete\", \"Single-lab observations\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identifying ASK1 phosphorylation at Ser83 and BAD inactivation established the molecular basis of PIM1-mediated anti-apoptosis under stress.\",\n      \"evidence\": \"In vitro and in vivo phosphorylation, site mutagenesis, downstream JNK/p38/caspase readouts; HOXA9-driven BAD phosphorylation with genetic rescue\",\n      \"pmids\": [\"19749799\", \"17327400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each survival substrate not quantified\", \"Cell-type dependence unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Phosphorylation of PRAS40 at Thr246 and subsequent AMPK/mTORC1 studies placed PIM1 within translational and metabolic control independently of AKT.\",\n      \"evidence\": \"In vitro kinase assay, co-IP showing mTOR complex disruption, inhibitor and Pim triple-knockout MEF metabolic and translation assays\",\n      \"pmids\": [\"19276681\", \"21187426\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect contributions to AMPK regulation not fully separated\", \"In vivo metabolic consequences in normal tissue unclear\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Demonstrating PIM1's cardioprotective role via AKT, Bcl-2/Bcl-XL, mitochondrial integrity, and progenitor division extended its function to tissue regeneration and stress survival.\",\n      \"evidence\": \"Pim-1 knockout and cardiac-specific transgenic mice, infarction models, mitochondrial integrity assays, asymmetric division quantification\",\n      \"pmids\": [\"18037896\", \"20203306\", \"20075333\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mitochondrial substrates of PIM1 not defined\", \"Mechanism of progenitor fate determination incomplete\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying HP1\\u03b3 Ser93 phosphorylation revealed a chromatin-level function, coupling IL-6/STAT3-induced PIM1 to heterochromatin formation and senescence.\",\n      \"evidence\": \"Co-IP, in vitro site-specific phosphorylation, ChIP for H3K9me3, ectopic expression and knockdown inducing senescence\",\n      \"pmids\": [\"25040935\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genome-wide scope of PIM1-dependent heterochromatin not mapped\", \"Reconciliation of pro-proliferative and pro-senescent roles unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Multiple regulatory studies established how PIM1 protein levels are controlled, defining Hsp90/Hsp70 stabilization, ubiquitin-proteasome degradation, and PP2A/B56\\u03b2-directed turnover, later extended by GSK-3\\u03b2 phosphorylation.\",\n      \"evidence\": \"Co-IP, geldanamycin and proteasome inhibitors, B56\\u03b2 knockdown with half-life measurement, GSK-3\\u03b2 inhibition and constitutive AKT experiments\",\n      \"pmids\": [\"11237709\", \"15798097\", \"17297438\", \"33568357\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"E3 ligase directing PIM1 ubiquitination not identified\", \"Hierarchy among regulatory inputs unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Distinguishing a kinase-independent scaffolding role showed PIM1 promotes IRF3-containing TLR signaling complexes for IFN-\\u03b2 production, broadening its function beyond catalysis.\",\n      \"evidence\": \"Pim1-/- macrophages and mice, kinase-dead comparison, co-IP of TRIF/TRAF3/TBK1/IRF3, poly(I:C) challenge; also implicated in RANKL/TAK1 osteoclast signaling\",\n      \"pmids\": [\"36446848\", \"21068407\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of scaffolding contacts undefined\", \"Extent of kinase-independent roles across pathways unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How PIM1 integrates its catalytic and scaffolding activities, and which substrates dominate in specific physiological versus oncogenic contexts, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified substrate hierarchy across cell types\", \"E3 ligase and full degradation circuitry incomplete\", \"In vivo relevance of individual phosphorylation events not systematically dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 1, 5, 9, 11, 16, 17, 18, 24]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 1, 8]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [27]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [7, 9, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [5, 6, 16, 24]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 6, 9]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [6]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [5, 9, 12]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [15, 18, 20]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [17, 21, 28]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [25, 27, 28]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [4, 10, 13, 26]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"HSP90AA1\", \"HSP90AB1\", \"CDC25C\", \"RUNX1\", \"RUNX3\", \"ASK1\", \"PRAS40\", \"HP1\\u03b3\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}